The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Portfolio Pulse from Benzinga Insights
Arcturus Therapeutics (NASDAQ:ARCT) has seen a variety of analyst ratings over the past three months, with a recent positive shift in sentiment. Four analysts have provided ratings, with the latest 12-month price targets showing an average of $63.25, up 14.31% from the previous $55.33. The company's financial performance has been strong, with significant revenue growth and above-average financial metrics compared to the industry. Arcturus focuses on RNA medicines for rare diseases, with a notable pipeline including LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
March 11, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has received positive analyst ratings, with an updated average 12-month price target of $63.25, indicating a bullish outlook. The company's strong financial performance and focus on RNA medicines for rare diseases contribute to its positive assessment.
The positive shift in analyst sentiment, reflected in the raised price targets and the company's strong financial performance, suggests a bullish outlook for ARCT in the short term. The company's focus on RNA medicines for rare diseases and its significant revenue growth are key factors contributing to this positive assessment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100